Headache Clinical Trial
Official title:
A Phase II Randomized Controlled Double-Blind Clinical Trial of Sphenopalatine Ganglion (SPG) Block for Headache After Concussion
Verified date | August 2022 |
Source | University of Michigan |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This clinical trial will enroll participants to evaluate the effects of SPG block on post-traumatic headache. The study hypothesizes that patients that receive a SPG block with lidocaine vs. placebo (saline) will have a lower number of headache days in the week following the procedure, and will also report lower symptom scores. Eligible participants will receive one treatment (SPG block) as well as complete surveys prior to and after receiving treatment (for a total of approximately 2 weeks).
Status | Terminated |
Enrollment | 2 |
Est. completion date | April 6, 2021 |
Est. primary completion date | April 1, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: - Diagnosed with a concussion and are greater than 14 days from the date of their injury. - Experiencing greater or equal than 4 occurrences of headache per week lasting at least 1 hour per occurrence with a headache severity score greater or equal to 2 out of 6. Exclusion Criteria: - Allergy to local anesthetics of the amide type (for example (i.e.) lidocaine) - Frequent epistaxis (i.e. more than one nose bleed per month), - Bleeding disorders - History of any of the following: nasal or facial fracture, nasal septal defect, any other craniofacial abnormality, hepatic disease, Adam-Stokes syndrome, Wolff-Parkinson-White syndrome, or severe degrees of sinoatrial, atrioventricular, or intraventricular heart block - Pregnant - Are at increased risk for methemoglobinemia (including patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, and concurrent exposure to oxidizing agents or their metabolites and drugs associated with methemoglobinemia) |
Country | Name | City | State |
---|---|---|---|
United States | University of Michigan | Ann Arbor | Michigan |
Lead Sponsor | Collaborator |
---|---|
University of Michigan |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mean Change in Headache Severity Score | Patients will rate their headache on a scale of 0 to 6, with 0 corresponding to "absent" and 6 corresponding to "severe." | 48 hours pre-SPG to 48 hours after SPG block | |
Secondary | Patient Global Impression of Change (PGIC) | A rating scale of global improvement which participants use a seven-point scale ("1" = very much improved, "4" = no change, "7" very much worse). Participants will rate their change at two hours and 24 hours following the SPG block procedure. | 2, 24 hours after SPG block | |
Secondary | Mean Change in the Number of Headache Occurrences | The number of headache episodes over the one week prior to the SPG block compared to one week after the procedure. | 1 week before SPG block, up to 1 week post SPG block | |
Secondary | Mean Headache Occurrences Within 48 Hours pre-and 48 Hours Post-SPG Block | The number of headache episodes prior to the SPG block to after the procedure. | 48 hours pre SPG to 48 hours post block | |
Secondary | Mean Headache Occurrences Within 1 Week Pre- and 1 Week Post-SPG Block | The number of headache episodes over the one week prior to the SPG block to one week after the procedure. | 1 week before SPG block up to 1 week post SPG block | |
Secondary | Mean Change in Headache Hours Per Day | The number hours with headache 1 week prior to the SPG block and for up to 1 week after the procedure. | 1 week before SPG block, up to 1 week post SPG block | |
Secondary | Mean Headache Hours Per Day Within 48 Hours Pre- and 48 Hours Post-SPG Block | 48 hours pre SPG up to 48 hours post SPG | ||
Secondary | Mean Headache Hours Per Day Within 1 Week Pre and 1 Week Post Block | 1 week before SPG block to 1 week post SPG block | ||
Secondary | Mean Change in the Number of Days With Headache | 1 week before SPG block, up to 1 week post SPG | ||
Secondary | Mean Number of Days With Headache in the1 Week Post-SPG Block Compared to 1 Week Pre-SPG Block. | 1 week before SPG block up to 1 week post SPG | ||
Secondary | Mean Change in As-needed Headache Treatment Uses | Patients will be asked to report the number of uses of as-needed headache medications used in the one week prior to the SPG block and after SPG block for up to one week after the procedure. | 1 week before SPG block to 1 week post SPG block | |
Secondary | Mean As-needed Headache Treatment Uses Within 48 Hours Pre- and 48 Hours Post-SPG | Patients will be asked to report the number of uses of as-needed headache medications used in the one week prior to the SPG block and after SPG block for up to one week after the procedure. | 48 hours before SPG block to 48 hours post SPG block | |
Secondary | Mean As-needed Headache Treatment Uses Within 1 Week Pre and 1 Week Post Block | Patients will be asked to report the number of uses of as-needed headache medications used in the one week prior to the SPG block and after SPG block for up to one week after the procedure. | 1 week before SPG block up to 1 week post SPG block |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT03472872 -
A Comparative Efficacy Trial of IV Acetaminophen Versus IV Ketorolac for Emergency Department Treatment of Generalized Headache
|
Phase 4 | |
Withdrawn |
NCT05410366 -
Safe Harbors in Emergency Medicine, Specific Aim 3
|
||
Withdrawn |
NCT02866084 -
Neuromodulation Treatment of Vestibular Migraines
|
N/A | |
Active, not recruiting |
NCT03537573 -
Provider-Targeted Behavioral Interventions to Prevent Unsafe Opioid Prescribing for Acute Pain in Primary Care
|
N/A | |
Recruiting |
NCT05891808 -
miR-155 Expression in Episodic and Chronic Migraine
|
||
Not yet recruiting |
NCT04352218 -
Safety Profile of PETALO CVS in the Treatment of Non-thrombotic Internal Jugular Vein Stenosis and Chronic Headache
|
Phase 2 | |
Completed |
NCT02734992 -
Acceptance and Commitment Therapy vs Medical Treatment as Usual Wait-list Control for Primary Headache Sufferers
|
N/A | |
Completed |
NCT01327118 -
Prostaglandin F2alpha in a Human Headache Model
|
N/A | |
Completed |
NCT01153789 -
Study of Oculomotor Dysfunction Leading to Children Vertigo
|
N/A | |
Not yet recruiting |
NCT00969995 -
Identification of Inflammatory Markers in Migraine Patients
|
N/A | |
Not yet recruiting |
NCT00752921 -
Randomized Placebo Controlled Trial With Etoricoxib That is Taken to Prevent the Yom Kippur Headache
|
Phase 4 | |
Completed |
NCT00212810 -
Evaluation of the Effectiveness of Topiramate in Preventing the Transformation From Episodic Migraine to Chronic Daily Headache.
|
Phase 4 | |
Terminated |
NCT00291395 -
PGI2 Induced Headache and Cerebral Haemodynamics in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00263094 -
An End to the Yom Kippur (and Ramadan) Headache
|
N/A | |
Completed |
NCT00135122 -
Prednisolone in the Treatment of Withdrawal Headache in Probable Medication Overuse Headache
|
Phase 3 | |
Completed |
NCT02475005 -
An Intervention to Improve Adolescent Headache Self-management
|
N/A | |
Completed |
NCT03163901 -
The Effect of OMT on Functional Outcomes and Anti-inflammatory Biomarkers in Mild to Moderate Traumatic Brain Injury
|
N/A | |
Completed |
NCT01664585 -
Exercise Training With Physically Active Lifestyle to Reduce Headache and Quality of Life
|
N/A | |
Completed |
NCT04632420 -
Evaluation of Headache and Childbirth in a Chronic Pain Population
|
||
Recruiting |
NCT05033613 -
Home Blood Pressure Monitoring Before and After COVID-19 Vaccination in Patients at High Risk of Cardiovascular Disease
|